| |
| |
|
| Insider
Information: |
Hirsch Andrew |
| Relationship: |
President & CEO, Direc... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
268,306 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$807,482 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
268,306 |
|
|
| Total
Value |
$807,482 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
DNIB Upwind Inc |
BIND |
Officer |
2013-09-19 |
31,293 |
|
0 |
Premium* |
|
|
Editas Medicine, Inc. |
EDIT |
Director |
2017-05-30 |
2,000 |
|
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Chief Financial Officer |
2020-04-22 |
24,272 |
2019-01-20 |
0 |
Premium* |
|
|
C4 Therapeutics, Inc. |
CCCC |
President & CEO, Direc... |
2024-02-15 |
210,741 |
2022-04-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2024-02-15 |
4 |
D |
$7.90 |
$51,824 |
D/D |
(6,560) |
210,741 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
103,400 |
217,301 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2023-08-30 |
4 |
D |
$2.93 |
$6,461 |
D/D |
(2,205) |
113,901 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2023-08-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
116,106 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
81,600 |
108,606 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2023-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
31,325 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2023-01-30 |
4 |
D |
$7.78 |
$33,602 |
D/D |
(4,319) |
27,006 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
22,500 |
0 |
- |
|
| CCCC |
C4 Therapeutics, Inc. |
President & CEO |
• • – |
2022-04-12 |
4 |
B |
$8.40 |
$84,000 |
D/D |
10,000 |
10,000 |
2.81 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-04-22 |
4 |
D |
$45.91 |
$88,469 |
D/D |
(1,927) |
24,272 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-04-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,893 |
26,199 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-04-14 |
4 |
D |
$40.64 |
$64,983 |
D/D |
(1,599) |
20,306 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,387 |
21,905 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-02-24 |
4 |
D |
$48.66 |
$51,385 |
D/D |
(1,056) |
16,518 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
17,574 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-02-18 |
4 |
D |
$52.01 |
$46,081 |
D/D |
(886) |
14,241 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2020-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,750 |
15,127 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2019-02-19 |
4 |
D |
$58.03 |
$47,643 |
D/D |
(821) |
12,374 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,750 |
13,195 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2019-01-22 |
4 |
D |
$52.82 |
$240,595 |
D/D |
(4,555) |
10,445 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Financial Officer |
• – – |
2019-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| EDIT |
Editas Medicine, Inc. |
Director |
– • – |
2017-05-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
- |
|
| BIND |
DNIB Upwind Inc |
Chief Financial OfficerOfficer |
• – – |
2013-09-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
31,293 |
|
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
